期刊文献+

基于癌症基因图集数据库与免疫组织化学方法分析SMARCB1对肝细胞癌早期诊断及预后的作用 被引量:2

Effect of SMARCB1 on early diagnosis and prognosis of hepatocellular carcinoma
下载PDF
导出
摘要 目的:通过研究SMARCB1在肝细胞癌(hepatocellular carcinoma,HCC)组织的表达,阐明其对HCC的早期诊断及预后的作用。方法:在癌症基因组图集(The Cancer Genome Atlas,TCGA)数据库中筛选出SMARCB1基因,运用免疫组织化学(immunohistochemistry,IHC)技术和TCGA分析SMARCB1在HCC组织和正常组织的表达情况,阐述其在HCC发生、发展进程中的作用。结果:IHC结果证实,与正常肝组织相比,HCC中SMARCB1的蛋白表达量显著上升(P<0.01)。IHC的结果显示SMARCB1的蛋白表达量与原发肿瘤分期呈正相关(P<0.05),即SMARCB1表达量越高,原发肿瘤分期越趋向晚期。TCGA的结果显示SMARCB1的高表达是HCC的独立预后因素(P<0.05)。结论:SMARCB1可能起着促癌基因的作用,临床上根据其在组织中的表达差异,可鉴别早期的HCC及良性组织,并可能有效地进行预后判断。 AIM: To illuminate the effect of SWI/SNF-related,matrix-associated,actin-dependent regulator of chromatin,subfamily b,member 1( SMARCB1) in early diagnosis and prognosis of hepatocellular carcinoma( HCC) by determining the clinical expression of SMARCB1 in HCC tissue and benign liver tissue. METHODS: The specific target gene SMARCB1 was selected from these genes by using The Cancer Genome Atlas( TCGA). SMARCB1 expression in HCC tissue and benign liver tissue was measured by immunohistochemistry. Further statistical analysis of TCGA was performed to illuminate the role of SMARCB1 on HCC occurrence and progression. RESULTS: Compared with the benign liver tissue,immunohistochemical staining showed that SMARCB1 expression was significantly up-regulated in the HCC tissue( P〈0. 01). In addition,SMARCB1 expression was significantly associated with advanced tumor stage( P〈0. 05). The relation between SMARCB1 expression at mRNA level and clinical prognosis was analyzed. The results indicated that high SMARCB1 expression was an independent prognostic factor for HCC( P〈0. 05). CONCLUSION: SMARCB1 may play a part as a carcinogenic gene in tumorigenesis. We can distinguish primary HCC samples from non-malignant samples according to its different clinical expression. High SMARCB1 expression probably predicts poor outcome in HCC patients.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2017年第4期754-757,共4页 Chinese Journal of Pathophysiology
基金 海南省自然科学基金资助项目(No.ZDXM2015080 No.309063) 广州市花都区科技和信息化局项目(No.15-HDWS-012)
关键词 肝细胞癌 SMARCB1 诊断 预后 Hepatocellular carcinoma SMARCB1 Diagnosis Prognosis
  • 相关文献

参考文献3

二级参考文献42

  • 1屠红,高海峰,马国豪,刘毅.肝癌中乙型肝炎病毒整合位点的研究[J].中华医学杂志,2006,86(18):1249-1252. 被引量:10
  • 2Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA Cancer J Clin,2005,55(2):74-108. 被引量:1
  • 3Mann CD,Neal CP,Garcea G,et al.Prognostic molecular markers in hepatocellular carcinoma:a systematic review[J].Eur J Cancer,2007,43(6):979-992. 被引量:1
  • 4Thomas MB,Zhu AX.Hepatocellular carcinoma:the need for progress[J].J Clin Oncol,2005,23(13):2892-2899. 被引量:1
  • 5Pilia G,Hughes-Benzie RM,MacKenzie A,et al.Mutation in GPC3,a glypican gene,cause the Simpson-Golabi-Behmel overgrowth syndrome[J].Nat Genet,1996,12(3):241-247. 被引量:1
  • 6Tangkijvanich P,Chanmee T,Komtong S,et al.Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers[J].J Gastroenterol Hepatol,2010,25(1):129-137. 被引量:1
  • 7Hsu HC,Cheng W,Lai PL.Cloning and expression of a developmentaly regulated transcript MXR7 in hepatocellular carcinoma:biological siganificance and temporospatial distribution[J].Cancer Res,1997,57(22):5179-5184. 被引量:1
  • 8Zhu Z,Friess H,Kleeff J,et al.Glypican-3 expression is markedly decreased in human gastric cancer but not in esophageal cancer[J].Am J Surg,2002,184 (1):78-83. 被引量:1
  • 9Xiang YY,Ladeda V,Filmus J.Glypican-3 expression is silenced in human breast cancer[J].Oncogene,2001,20(50):7408-7412. 被引量:1
  • 10Kim H,Xu GL,Borczuk AC,et al.The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor[J].Am J Respir Cell Mol Biol,2003,29(6):694-701. 被引量:1

共引文献49

同被引文献13

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部